Efficacy of vasoactive medications in neonatal shock.

Use of inotropic agents in treatment of neonatal shock:A randomized controlled stuy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044266

Enrollment

Unknown

Registered

2021-03-14

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal shock

Interventions

Dopamine group:Initiate of dopamine

Dobutamine group:Initiate of dobutamine

epinephrine group:Initiate of epinephrine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. GA: 28-44 weeks; 2. Infants were diagnosed(Shock Score>=3) and cardiac index <=3.3L/min*m2; 3. Parents provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Congenital structural heart disease, except patent foramen ovale and non-hemodynamically significant patent ductus arteriosus; 2. Major congenital malformations and chromosomal anomalies; 3. Hemorrhagic shock, obstructive shock, persistent pulmonary hypertension, cardiac arrest and end-stage of shock; 4. Infants received inotropic agents before entry into the study; 5. Infants were unavailable for echocardiography.

Design outcomes

Primary

Measure	Time frame
Correction of shock;Duration of shock;Mortality;	—

Countries

China

Contacts

Public ContactYe Xiuzhen

Guangdong Women And Children's Hospital

yxzh328@126.com+86 13725116591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026